Episode 128: Debate of the Decade: RCTs in the Era of Precision Oncology
Healthcare Unfiltered
00:00
The Importance of Surrogate Endpoints in Oncology
Vivek: I think randomized trials are the ones in oncology that have actually been permissive for mediocre improvements. We want to move away from standard of care, where in a lot of solid tumors, standard of care means in two years, you're going to die. And what we really want is drugs that make such significant improvements that they don't need a randomized trial or a randomized trial becomes unethical. So again, with the newer therapies, we can visually see these response rates are 50 to 80%. They're not marginal response rates. and we can see our patients living longer.
Play episode from 34:22
Transcript
